相关产品推荐更多 >

Scavenger Receptor Class A Member 5 (SCARA5) Antibody (HRP)/Scavenger Receptor Class A Member 5 (SCARA5) Antibody (HRP)/Scavenger Receptor Class A Member 5 (SCARA5) Antibody (HRP)
询价
Rabbit polyclonal antibody to human Mitofusin 2 (601-757): Affinity purified/Rabbit polyclonal antibody to human Mitofusin 2 (601-757): Affinity purified/Rabbit polyclonal antibody to human Mitofusin 2 (601-757): Affinity purified
询价
TTYH1抗体(C末端)|TTYH1 Antibody (CT) (Tweety homolog 1)
询价
FES 多克隆抗体 | FES polyclonal antibody
询价
Oxidoreductase HTATIP2 (HTATIP2) Antibody/Oxidoreductase HTATIP2 (HTATIP2) Antibody/Oxidoreductase HTATIP2 (HTATIP2) Antibody
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
Partial recombinant protein of human catenin delta-2 (amino acids 1081 to 1190) with a GST tag.
- 亚型:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 形态:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 保存条件:
厂家建议常温运输。抗体溶解之后,建议分装保存于-20℃。当保存于4℃时,应添加适量的抗生素。请避免反复冻融。
- 克隆性:
单克隆
- 标记物:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 适应物种:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 保质期:
根据订购时间与产品批次判定,欢迎联系艾美捷咨询确认
- 抗原来源:
小鼠
- 目录编号:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 级别:
一抗
- 库存:
小鼠来源毒性抗体:人catenin delta-2【6E11】:IgG
- 供应商:
艾美捷
- 宿主:
小鼠
- 应用范围:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 浓度:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 靶点:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 抗体英文名:
Mouse monoclonal antibody to human catenin delta-2【6E11]: IgG
- 抗体名:
小鼠来源毒性抗体:人catenin delta-2【6E11】:IgG
- 规格:
100ug
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Generation of Antibody Molecules Through Antibody Engineering
been overcome to a large extent using genetic-engineering techniques to produce chimeric mouse/human and completely human antibodies. Such an approach is particularly suitable because of the domain structure of the antibody molecule ( 2 ), where functional
ANTIBODY BINDING TO PROTEIN A AND PROTEIN G
A Protein G Human IgG1 ++++ ++++ Human IgG2 ++++ ++++ Human IgG3 - ++++ Human IgG4 ++++ ++++ Mouse IgG1 + ++++ Mouse IgG
技术资料暂无技术资料 索取技术资料





